奥沙利铂联合培美曲塞治疗晚期胃癌患者的临床疗效及对炎症因子及PG水平的影响  

Clinical Effect of Oxaliplatin Combined with Pemetrexed in Treatment of Advanced Gastric Cancer and Its Effect on Level of Inflammatory Factors and PG

作　　者：高本岭 王家锋 杨向东[1] GAO Benling;WANG Jiafeng;YANG Xiangdong(Department of General Surgery,Cangxi Hospital of Traditional Chinese Medicine,Cangxi 628400,China)

机构地区：[1]苍溪县中医医院普外科,四川苍溪628400

出　　处：《医学综述》2020年第5期1036-1040,共5页Medical Recapitulate

摘　　要：目的探讨奥沙利铂联合培美曲塞治疗晚期胃癌患者的疗效及对炎症因子及胃蛋白酶原(PG)水平的影响。方法选取2017年6月至2018年6月苍溪县中医医院普外科收治的晚期胃癌患者88例,按照治疗方法不同分为对照组和研究组,各44例。对照组仅给予培美曲塞治疗,培美曲塞500 mg/m^2加100 m L 0.9%氯化钠注射液,静脉滴注,治疗2个月;研究组给予奥沙利铂联合培美曲塞治疗,第1天静脉滴注奥利沙铂130 mg/m^2(溶于250~500 m L 5%葡萄糖溶液),培美曲塞用法用量同对照组,3周重复1次,治疗2个月。比较两组患者的临床疗效,治疗前后炎症因子[白细胞介素-6(IL-6)、基质金属蛋白酶9(MMP-9)、血管内皮生长因子C(VEGF-C)]、PG水平变化,不良反应发生率以及生存概率。结果研究组总有效率高于对照组[95.5%(42/44)比75.0%(33/44)](P<0.05)。治疗前两组患者炎症因子(IL-6、MMP-9、VEGF-C)及PGⅠ、PGⅡ、PGR比较差异无统计学意义(P>0.05),研究组治疗后上述指标均低于对照组,两组各指标组间、时点间、组间和时点间交互作用差异有统计学意义(P<0.01)。两组患者白细胞减少、贫血、血小板减少、恶心呕吐及总不良反应发生率比较差异均无统计学意义(P>0.05)。研究组治疗后1年生存概率高于对照组[47.7%(21/44)比27.3%(12/44)](P<0.05)。结论奥沙利铂联合培美曲塞治疗晚期胃癌患者临床效果显著,可明显降低炎症因子水平,改善PG水平,提高生存概率。Objective To investigate the effect of oxaliplatin combined with pemetrexed on the level of inflammatory factors and pepsinogen(PG)in patients with gastric cancer.Methods From Jun.2017 to Jun.2018,88 patients with advanced gastric cancer admitted to Department of General Surgery of Cangxi County Hospital of Traditional Chinese Medicine were included in the study,and divided into a control group and a study group according to different treatment methods,44 cases in each group.The control group was only treated with pemetrexed,500 mg/m^2 added with 100 m L of0.9%sodium chloride injection,intravenous drip,for 2 months;the study group was treated with oxaliplatin combined with pemetrexed,on the first day of intravenous drip,130 mg/m^2 of oxaliplatin was used for injection(dissolved in 250-500 m L of5%glucose solution),pemetrexed dosage was the same as the control group,repeated once every 3 weeks,treated for2 months.The clinical effects,changes of inflammatory factors[interleukin-6(IL-6),matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor-C(VEGF-C)]and PG levels before and after treatment,incidence of adverse reactions and survival probability were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group[95.5%(42/44)vs 75.0%(33/44)](P<0.05).There was no significant difference in inflammatory factors(IL-6,MMP-9,VEGF-C)and PGⅠ,PGⅡand PGR in the two groups before treatment(P>0.05);after treatment,the above mentioned indexes of the study group were lower than those of the control group,and the differences between groups,time points,and interactions of groups and time points were statistically significant(P<0.01).There was no significant difference in the incidences of leucopenia,anemia,thrombocytopenia,nausea and vomiting and total adverse reactions between the two groups(P>0.05).The 1-year survival rate of the study group was higher than that of the control group[47.7%(21/44)vs 27.3%(12/44)](P<0.05).Conclusion Oxaliplatin combined

关 键 词：胃癌 奥沙利铂 培美曲塞 血管内皮生长因子C 白细胞介素-6 基质金属蛋白酶9 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]